Aim Pentoses are widely abundant in organic food. Thermal treatment of pentoses leads to the formation of norfuraneol (NF). The aim of this study was to show whether NF, which is taken up regularly, for example with cooked food, affects the human endothelial nitric oxide synthase (eNOS) system. Methods and results The study was performed using cultured human umbilical vein endothelial cells (HUVEC), HUVEC-derived EA.hy926 cells, and bovine aortic endothelial cells. Nitric oxide (NO) release and eNOS activity were measured using diaminofluorescein-2 and [
C]L-arginine/[
14 C]L-citrulline conversion. Levels of (phospho-)eNOS were detected by western blotting. Reactive oxygen species (ROS) production was assessed using 2 0 ,7 0 -dichlorodihydrofluorescein diacetate. Pharmacokinetic parameters of NF were calculated by VolSurf software. NF dose dependently increased eNOS activity and NO release (30-300 mM), but did not affect total eNOS protein or cellular ROS levels. The increase in eNOS activity coincided with specific dephosphorylation of eNOS-Thr 495 , known to enhance eNOS activity. Inhibition of protein phosphatase 1 (PP1) by calyculin A, tautomycetin, or siRNA against PP1 reversed NF-induced eNOS-Thr 495 dephosphorylation. Phosphorylation at eNOS-Ser 1177 was not significantly altered by NF. Inhibition of protein kinase C with bisindolylmaleimide I (GFX) or calphostin C mimicked the effect of NF. In contrast to GFX, however, NF had no effect on phorbol-12-myristate-13-acetate-induced endothelial ROS formation. In silico, NF is stable towards CYP3A4 metabolism, shows low protein binding, and high tissue distribution. Conclusion NF enhances endothelial NO release most likely by promoting specific dephosphorylation of eNOS-Thr 495 via PP1 in vitro and may be a promising compound to enhance endothelial function in vivo.
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Introduction
A key event in the development of atherosclerosis is endothelial dysfunction, characterized by a reduced capacity of endothelial cells to suppress processes of inflammation, thrombosis, and oxidative stress. Clinical and experimental data have established the production of nitric oxide (NO) by the endothelial nitric oxide synthase (eNOS) as a critical factor for the maintenance of a healthy endothelium and vascular homeostasis: NO regulates vasomotor tone and exerts anti-atherogenic effects on vascular smooth muscle cells, platelets, and inflammatory cells. 1, 2 Increasing NO bioavailability in the vasculature is considered a strategy to prevent the onset of cardiovascular diseases and is therefore of pharmacological interest. 3 It is well known that dietary habits are playing an important role in the development of cardiovascular diseases. 4 While a 'Western diet' is associated with increased cardiovascular risk, a 'Mediterranean diet' can lower it, 5 suggesting that the daily diet has the potential to modulate eNOS function. Indeed, positive effects on endothelial NO production have been demonstrated for compounds found in red wine, green tea, pomegranates, or soy beans. [6] [7] [8] [9] [10] [11] Pentoses are naturally occurring monosaccharides ubiquitously present in organic food. D-ribose, for example, serves as a linker component within RNA in all living organisms. In the form of pentosans, pentoses can also be found in plants reaching concentrations of 2-6% in wheat or rye flour. 12 Thermal decomposition of pentoses, e.g. during cooking, leads to the formation of the conversion product norfuraneol (4-hydroxy-5-methyl-3(2H)-furanone, NF, Figure 1A ). NF has been described as a major component of meat broth. 13 It is also found in other foods, such as in soy sauce 14 or coffee, 15 and is used as a flavour component. Chemically, NF can be considered as a reductone and is thus potentially redoxactive, a feature NF may share with known eNOS modulators such as plant-derived polyphenols. [6] [7] [8] [9] [10] [11] Since NF is present in relevant amounts in the daily diet, we examined its putative effect on the human eNOS system.
Methods

Chemicals and cell culture reagents
Dulbecco's modified Eagle's medium (DMEM) without phenol red containing 4.5 g/L glucose, endothelial growth medium EBM TM , EBM TM SingleQuots, HAT supplement (100 mM hypoxanthine, 0.4 mM aminopterin, 16 mM thymidine), glutamine, benzylpenicillin, streptomycin, and amphotericin B were bought from Lonza (USA). Trypsin and fetal bovine serum (FBS) were obtained from Invitrogen (USA). G418 sulfate was purchased from PAA Laboratories GmbH (Austria). Phorbol-12-myristate-13-acetate (PMA), 4,5-diaminofluorescein (DAF-2), ionomycin, bisindolylmaleimide I (GFX), calphostin C (CAC), calyculin A (CYA), okadaic acid (OKA), and cyclosporine A (CSA) were bought from Alexis Biochemicals (Switzerland), tautomycetin (TAU) from Tocris Bioscience (UK), ) from Cell Signaling (USA), tubulin and horseradish peroxidase-conjugated goat anti-mouse secondary antibody from Santa Cruz (USA), horseradish peroxidase-conjugated goat anti-rabbit secondary antibody from Upstate (USA). All other chemicals were bought from Sigma-Aldrich (USA). Thin layer chromatography plates were bought from Machery-Nagel (Germany). NF and ascorbic acid were dissolved in ultra-pure water, filtrated through a 0.22 mm filter and stored at 2808C as 1000-fold stock solutions. CAC, CYA, CSA, GFX, OKA, RV, TAU, and PMA were dissolved in dimethyl sulphoxide as 1000-fold stock solutions and stored at 2808C.
Synthesis of norfuraneol (4-hydroxy-5-methyl-3(2H)-furanone, NF)
Three grams of xylose and 3 g of beta-alanine were dissolved in 50 mL water containing 2 g of disodium phosphate and 1 g of dipotassium phosphate. After boiling for 30 min the solution was extracted with ethyl acetate and the organic phase was purified using a silica gel column. Structure and purity (.99%) were confirmed by high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and melting point analysis, which corresponded to literature. 16 
Cell culture
The endothelial cell line EA.hy926 (kindly provided by Dr C.-J.S.E., University of North Carolina, Chapel Hill, NC), which is derived from human umbilical vein endothelial cells (HUVEC), 17 was cultivated as described previously (see Supplementary data for detailed information). 18 HUVEC were isolated from umbilical cords obtained from a local hospital as described 19 and cultivated in EBM growth medium supplemented with 10% FBS, EBM SingleQuots, 100 U/mL benzylpenicillin, 100 mg/mL streptomycin, and 1% amphotericin until passage six. For experiments, cells were seeded in gelatinecoated six-well plates at a density of 8 Â 10 5 cells/well. Bovine aortic endothelial cells (BAoEC) were purchased from Genlantis (USA) and cultured according to the supplier's instructions. Basic cell parameters were routinely checked using a cell viability analyser (ViCell TM , Beckman Coulter, CA, USA).
Citrulline is produced from arginine by eNOS in equimolar amounts to NO and can thus serve as a surrogate marker of NO production. The assay was performed as previously described. 18 Briefly, cells were equilibrated in (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) buffer, then 0.32 mM 14 C]L-citrulline was quantified by autoradiography in a phosphorimager (BAS-1800II, Fujifilm, Japan). AIDA software (raytest USA Inc., USA) was used for densitometric analysis.
Quantification of nitric oxide release by diaminofluorescein-2
Quantification of NO released by EA.hy926 or BAoEC was performed using the NO-sensitive fluorescent probe diaminofluorescein-2 (DAF-2) 20 as described previously. 18 Briefly, cells were equilibrated in phosphate buffered saline (PBS) containing calcium, magnesium, and arginine (100 mM) before addition of ionomycin (1 mM) and DAF-2 (0.1 mM) followed by incubation at 378C for 30 min. Fluorescence of the supernatant was measured in a desktop fluorometer (RF 1501, Shimadzu, Japan). 
Determination of total reactive oxygen species production
Total cellular reactive oxygen species (ROS) production was analysed by flow cytometry after loading of cells with the fluorogenic probe H 2 DCF-DA and performed essentially as described (see Supplementary data for detailed information). 21 The geometric mean of log fluorescence of 10 000 cells (corrected for autofluorescence) of each treatment group was taken as a measure for the total ROS load.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis and immunoblotting
Sample preparation, electrophoresis, and western blot were performed essentially as described. 6, 22 Detailed information can be found in the Supplementary data.
Silencing of protein phosphatase 1
Cells were seeded into six-well plates and at a confluence of 60% (EA.hy926) and 90% (HUVEC), respectively, transfected with 200 nM siRNA using the OptiMEM/Oligofectamine system (Invitrogen, USA) according to the manufacturer's instructions. siRNA targeting PP1 (sc-43545) was obtained from Santa Cruz (USA), unspecific scrambled control RNA from Invitrogen (USA). Seventy-two hours after transfection, cells were used for experiments. Knockdown of PP1 was examined by western blot analysis employing an antibody directed against the catalytic subunit of PP1 (sc-443; Santa Cruz).
Ribonucleic acid analysis
Total RNA was isolated with peqGOLD total RNA Kit (peqlab, Germany) according to the manufacturer's protocol. cDNA was synthesized from 5 mg of total RNA using Superscript TM II Reverse Transcriptase (Invitrogen, USA), purified on Micro Bio-Spin 30 Tris Columns (BIO-RAD, USA), and assayed by quantitative real-time PCR on a LightCycler TM 480 (Roche Diagnostics, Switzerland) using Lightcycler TM 480 SYBR Green I Master Mix (Roche Diagnostics, Switzerland). Detailed information can be found in the supplemental methods section.
In silico predictions of the pharmacokinetic profile of norfuraneol
VolSurf 23 is a computational procedure to produce 2D molecular descriptors from 3D molecular interaction energy grid maps. VolSurf working examples are extensively reported. [24] [25] [26] [27] [28] By the use of multivariate statistics coupled with interactive 2D and 3D plots, insights for drug design, pharmacokinetics profiling, and screening are obtained. For NF, we used the protein binding (PB), volume distribution (VD), and CYP3A4 metabolic stability (MetStab) models. For details of each model please refer to the supplemental methods section.
Statistical methods
Statistical analysis was done using GraphPad Prism software version 4.03 (GraphPad Software Inc., USA). Normalized data were transformed logarithmically [Y¼log(Y )] before analysis. One-way analysis of variance combined with Dunnett's post-test was used for the comparison of multiple treatment groups with the control. If two groups were compared, two-tailed paired t-test was applied. P,0.05 was considered significant. All graphs are showing means+SEM.
Results
Norfuraneol enhances eNOS activity and endothelial nitric oxide release
To investigate a putative effect of NF ( Figure 1A ) on eNOS activity, we first performed an [
14 C]L-arginine/ [ 14 C]L-citrulline conversion assay using HUVEC-derived EA.hy926 cells, 17 which are characterized as a stable endothelial cell line. 29, 30 EA.hy926 cells treated with 30-300 mM NF for 18 h showed a significantly higher [
14 C]L-citrulline production than untreated control cells (P , 0.01, Figure 1B ). This effect was concentration-dependent and could be blocked by the specific eNOS inhibitor N v -nitro-L-arginine (L-NNA). As a positive control we used ascorbic acid, which is known to stabilize the eNOS cofactor tetrahydrobiopterin and thereby to enhance eNOS activity. 31 Since NO can be degraded intracellularly by superoxide derived from enzymatic sources, we quantified NO released by endothelial cells using the NO-sensitive fluorogenic probe DAF-2. 20 Incubation of cells with NF (30-300 mM) for 18 h significantly increased NO release compared with control cells (P , 0.01, Figure 1C ). Addition of L-NNA again abolished the effect of NF, indicating the specificity of the obtained fluorescence signal for eNOS-derived NO. Incubation with PMA (2 nM) for 18 h, which increases NO release due to upregulation of eNOS as well as downregulation of protein kinase C (PKC), 32 was used as a positive control. Similar results were obtained in BAoEC, in which 100 mM NF increased endothelial NO release by approximately 40%. Cell viability-determined by trypan blue exclusion-remained higher than 95% after NF treatment (data not shown).
Norfuraneol enhances eNOS activity in a time-dependent manner
Increased NO production may be the consequence of enhanced eNOS gene transcription resulting in higher eNOS protein levels. However, we were not able to detect any significant differences in eNOS protein levels after NF-treatment for 24 h (see Supplementary material online, Figure S1 ). Next we examined the kinetics of the NF-induced eNOS activation. EA.hy926 cells stimulated with NF for different periods of time (30 min to 24 h) were subjected to the [ 14 C]L-arginine/[ 14 C]L-citrulline conversion assay ( Figure 2A) . As early as 2 h after NF treatment endothelial [ 14 C]L-citrulline production was significantly increased (P , 0.05) and remained elevated for at least 24 h (P , 0.01). Cycloheximide (10 mg/mL), an inhibitor of protein biosynthesis, was not able to block this increase (Schmitt, unpublished observation, 2008) indicating that de novo synthesis of eNOS and/or an activating eNOS-associated protein, such as heat shock protein 90, 33 is not required for the action of NF. These results suggest that NF has a direct and immediate effect on eNOS activity.
Norfuraneol promotes dephosphorylation at eNOS-threonine 495
eNOS is tightly regulated by phosphorylation of specific amino acid residues. Phosphorylation at serine 1177 (human sequence) as well as dephosphorylation at the constitutively phosphorylated threonine 495 are both known to increase eNOS enzymatic activity. 34 We checked the phosphorylation status of eNOS at these key regulatory sites at timepoints when increased eNOS activity was first detectable (0.5-2 h). Stimulation of endothelial cells with 100 mM NF led to dephosphorylation of eNOS-Thr 495 within 30 min (P 0.01, Figure 2B ). Interestingly, the phosphorylation status of Ser 1177 did not change significantly, despite a reproducible trend towards slightly increased phosphorylation. To corroborate the effect of NF on eNOS phosphorylation, we repeated the experiment in primary endothelial cells. Consistent with the findings in EA.hy926 cells, NF also led to dephosphorylation of eNOS-Thr 495 in HUVEC within 2 h (P , 0.01, Figure 2C ). These data indicate that NF induces rapid changes of the eNOS phosphorylation status which are associated with enhanced enzymatic activity and coincide precisely with the measured increase in NO production (see Figure 2A ).
Effect of norfuraneol in the presence of protein kinase C inhibitors
PKC is considered to be the predominant kinase acting on eNOS-Thr 495 . 1, 34 To study whether inhibition of PKC may account for the observed decrease in eNOS-Thr 495 phosphorylation we treated endothelial cells with the pan-PKC inhibitors CAC 35 and GFX. 36 Incubation with CAC (0.25-1 mM) for 1.5 h led to gradual dephosphorylation at eNOS-Thr 495 ( Figure 3A) . Addition of NF during the last 60 min decreased the phosphorylation level even further ( Figure 3A) , suggesting that NF either intensified PKC inhibition or activated an alternative pathway promoting eNOS-Thr 495 dephosphorylation. Similarly, treatment with GFX (10 mM) mimicked the effect of NF although co-stimulation with NF did not lower eNOS-Thr 495 phosphorylation additionally ( Figure 3A) . Pre-treatment of EA.hy926 cells with NF also significantly decreased ( Figure 3B ) the effect of the PKC activator PMA, 32 which is known to promote phosphorylation at eNOS-Thr 495 . 32, 37 Contrary to the PKC inhibitor GFX, however, NF failed to block the stimulatory action of PMA on ROS production 38 in HUVEC ( Figure 3C ) and EA.hy926 cells (data not shown) arguing against a universal inhibitory action of NF on PKC.
Inhibition and silencing of protein phosphatase 1 blocks norfuraneol-induced eNOS-threonine 495 dephosphorylation
Since we have seen that NF can synergize with PKC inhibitors regarding the phosphorylation of eNOS-Thr 495 , we further investigated whether NF promotes dephosphorylation via activation of phosphatases acting on eNOS-Thr 495 . Protein phosphatase 1 (PP1), protein phosphatase 2A (PP2A), and calcineurin (PP2B) have been described to be involved in the dephosphorylation of this site (reviewed in Mount et al. 34 ). We applied specific phosphatase inhibitors and investigated whether these affect the ability of NF to induce dephosphorylation of eNOS-Thr 495 . CSA, an inhibitor of PP2B, 39 did neither alter the basic phosphorylation level of eNOS-Thr 495 nor could pre-treatment with CSA block the effect of NF (data not shown) denying a major role of PP2B for the action of NF. OKA (100 nM), which selectively inhibits PP2A, 32, 40 was not able to block the action of NF ( Figure 4A ). Basal phosphorylation levels were lowered by 200 nM OKA at eNOS-Thr 495 but did not enhance NF-induced dephosphorylation ( Figure 4B ). CYA is a phosphatase inhibitor with specificity towards PP1. 40 Pretreatment of cells with 1 nM CYA, which did not affect basal phosphorylation levels at eNOS-Thr 495 , completely abolished the effect of NF ( Figure 4A) . Consistent results were obtained using 5 nM CYA, which strongly increased basal eNOS-Thr 495 phosphorylation ( Figure 4B ) and TAU (0.1-1 mM) as an alternative PP1 inhibitor ( Figure 4C) . 41 Since these results indicate that PP1 might be the mediator of NF-induced dephosphorylation at eNOS-Thr 495 , we further investigated the role of PP1 in this process by the silencing of PP1 in HUVEC and EA.hy926 cells using siRNA. The silencing of PP1 enhanced basal phosphorylation and completely prevented NF-induced dephosphorylation of eNOS-Thr 495 , confirming that PP1 may mediate the effect of NF and underlining the important role of PP1 in the regulation of eNOS-Thr 495 phosphorylation. 40 
Norfuraneol does not alter cellular reactive oxygen species production or NAD(P)H oxidase 4 expression
There are data indicating that dephosphorylation of eNOS-Thr 495 may lead to eNOS uncoupling, forcing eNOS to ]L-citrulline production was normalized to the control (*P , 0.05; **P , 0.01; ns, not significant) (mean+SEM, n ¼ 3). (B) EA.hy926 cells were stimulated with 100 mM NF for 30-120 min. Cells were lysed, proteins were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis and subjected to western blot analyses for (phospho-)eNOS and tubulin. One representative blot is shown. Band intensities were normalized to tubulin (**P , 0.01; ns, not significant) (mean+SEM, n ¼ 3). (C ) Human umbilical vein endothelial cells were treated with 100 mM NF for 1-2 h before being harvested for detection of (phospho-)eNOS and tubulin by western blot analyses. One representative blot is shown. Band intensities were normalized to tubulin (**P , 0.01; ns, not significant) (mean+SEM, n ¼ 4). produce superoxide instead of NO. 37 As a result, essential eNOS cofactors as well as NO itself are degraded and a vicious circle of further eNOS uncoupling follows. 1 We therefore determined whether long-term treatment with NF affected cellular ROS production. Incubation of cells with NF for 24 h did not alter total cellular ROS production (Supplementary material online, Figure S2A ). PMA, which is known to enhance ROS production in endothelial cells, 42 significantly increased, whereas the flavoprotein inhibitor diphenyleneiodonium chloride decreased ROS (P , 0.01 and P , 0.001, respectively). NAD(P)H oxidases are major sources of ROS and isoform 4 (Nox4) is the most abundantly expressed in endothelial cells. 43 Since Nox4 can be upregulated under conditions of oxidative stress, we assessed Nox4 mRNA expression. In line with the previous findings, treatment with NF for 24 h did not affect Nox4 expression in endothelial cells (Supplementary material online, Figure  S2B ), whereas PMA more than doubled Nox4 mRNA levels (P , 0.05).
Norfuraneol shows promising pharmacokinetic properties in silico
In order to get a first insight in the pharmacokinetic profile of NF we ran in silico calculations using VolSurfþ software. It can predict certain pharmacokinetic parameters of compounds based on the comparison with profiles of a collection of.500 related, but chemically diverse entities. 23 For NF, the software predicted a high concentration of free drug in the plasma because only 31% of it may bind to human serum albumin (HSA). Usually, the range of HSA binding lies between 10% and 100% depending on the compound. In a VD model NF scored 20.38 which translates into high achievable concentrations in tissues. In the metabolic stability model, NF obtained a value of 0.98. This means that NF remained practically unmetabolized after 60 min of incubation at 378C with a defined concentration of CYP3A4-enriched microsomal proteins ( Table 1) .
Discussion
In this study we show that NF, a compound found in cooked food, enhances eNOS activity in cultured human endothelial cells. This was associated with specific dephosphorylation of eNOS-Thr 495 that could be reversed by inhibition or silencing of PP1 and was mimicked by inhibition of PKC. NF had no effect on eNOS-Ser 1177 phosphorylation, total eNOS levels, or endothelial ROS production.
One of our key findings is the specific dephosphorylation of eNOS- phosphorylation likely via a PP1-mediated mechanism, we cannot exclude that NF is also affecting other phosphorylation sites known to regulate eNOS activity. 34 It remains open how NF promotes PP1 activation. It is important to emphasize that at this point we cannot discriminate between a direct increase of the enzymatic activity of PP1 by NF or any indirect effect that increases the impact of PP1 on eNOS phosphorylation (e.g. alteration of interaction partners, cellular localization, or substrate availability by NF). PP1 activity is regulated via interaction of the catalytic subunit with over 50 regulatory subunits, but no redox-sensitive way of PP1 regulation has been identified so far. 45 Interestingly, dephosphorylation at eNOS-Thr 495 is also observed upon treatment with hydrogen peroxide, suggesting that a yet unknown redox-sensitive NF was subjected to in silico calculations using VolSurf software. Results obtained with models for protein binding (PB), volume distribution (VD), and metabolic stability (MetStab) are depicted. Details concerning the software and its models can be found in the (supplemental) methods section.
pathway may regulate the phosphorylation status at that site. 44 In this context we also tested whether NF might alter endogenous endothelial hydrogen peroxide production but did not detect any changes within the first 2 h after treatment with NF, the time frame when dephosphorylation of eNOS-Thr 495 occurred (data not shown). In a study by Lin et al., 37 dephosphorylation of Thr 495 has been associated with eNOS uncoupling, although these results have been challenged recently. 46 The resulting vicious circle of increased superoxide and decreased NO production plays an important role in the development of vascular diseases. 1 We have demonstrated that treatment over 24 h with NF had no influence on total ROS production and did not alter the expression of Nox4, a prominent source of ROS in endothelial cells. Furthermore, we measured increased endothelial NO release 24 h after incubation with NF. Thus, we consider it unlikely that a treatment with NF and the ensuing dephosphorylation of eNOS-Thr 495 lead to eNOS uncoupling or enhanced oxidative stress under our culture conditions. Although NF is produced by thermal treatment of certain pentoses and has the potential to be taken up regularly with food, there are no data available yet regarding its absorption or metabolism. In contrast to some other bioactive dietary compounds, such as resveratrol, NF seems to be more abundantly present, at least in cooked foods since it is a breakdown product of ubiquitously present pentoses. In silico quantitative modelling predicts NF to possess low affinity for HSA and to resist metabolic conversion by CYP3A4. These properties suggest a good availability of NF in blood plasma potentially leading to high concentrations in tissues. A strong tendency towards tissue accumulation was further confirmed in a VD model. We therefore believe that the NF concentration used in our study (as low as 30 mM) is not necessarily beyond achievable levels in humans. Although very promising, such theoretical calculations cannot substitute a thorough pharmacokinetic analysis in vivo. It further remains to be seen whether NF also exerts the described effects in isolated vessels or has beneficial effects on endothelial function in vivo.
Taken together, we have shown that NF, a compound found in relevant amounts in cooked food, is able to increase endothelial NO production and eNOS activity in cultured human endothelial cells presumably due to specific dephosphorylation of eNOS at Thr 495 via a mechanism involving predominantly the activation of PP1. An additional inhibition of PKC by NF, however, cannot be ruled out at the moment. The specific targeting of eNOS-Thr 495 seems to be a so far unique pharmacological property. In silico, NF exerts stability towards CYP3A4 metabolism, low PB, and high tissue distribution. If these findings can be confirmed in vivo, NF might represent a promising dietary compound with vasoprotective properties.
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